Current consumer preference trends and increasing government regulation continue to drive interest in reduced antibiotic use and increased use of antibiotic alternatives, such as yeast probiotics. ActiSaf^® HR+ is a protected, proprietary strain of saccharomyces cerevisiae yeast is among the most commonly used probiotics in swine feeding programs. Usage has increased as pork producers and nutritionists continue to seek effective gut health and growth performance solutions that are not medications and are not rendered blood proteins. ActiSaf^® HR+ confers benefit to pigs through several mechanisms, including direct binding of pathogenic bacteria, increasing cooperative activity of gut microbiota, reduced intercellular permeability, and immune stimulation via dendrite and macrophage activation pathways. Additionally, ActiSaf^® HR+ helps prevent pathogen colonization on the intestinal mucosal through direct antagonism and competitive inhibition. This is caused by the binding of certain pathogenic bacteria, including e. coli and salmonella to the yeast cell wall components (Figure 1). Preferential adhesion and accumulating agglutination of the pathogenic bacteria to ActiSaf^® HR+ causes removal from the digestive tract as well as limiting adhesion to the intestinal wall (Table 1). As expected, when pathogenic challenges are acute, increasing the dosage of ActiSaf^® HR+ for a short duration can reduce inflammation and improve performance by effectively binding larger quantities of pathogenic bacteria and allowing the pig a greater opportunity to mount an effective immune response to the remaining pathogens (Figures 2 & 3).